



Tangram Therapeutics plc
("Tangram" or "the Company")

Results of Annual General Meeting

London, UK, 29 July 2026 – Tangram Therapeutics ("Tangram"), a company committed to uniting computation and RNAi to make better medicines faster, announces that at its Annual General Meeting held earlier today, all resolutions, as set out in the Notice of Meeting, were duly passed.

Resolution	Votes For	%	Votes Against	%	Abstentions	Resolution Result
Ordinary Resolution 1	513,343,657	99.99	18,000	0.01	0	Passed
Ordinary Resolution 2	513,343,657	99.99	18,000	0.01	0	Passed
Ordinary Resolution 3	513,343,657	99.99	18,000	0.01	0	Passed
Ordinary Resolution 4	513,315,506	99.99	20,271	0.01	25,880	Passed
Special Resolution 5	512,905,423	99.92	430,354	0.08	25,880	Passed

About Tangram Therapeutics

Tangram Therapeutics is a clinical-stage biotech company committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster. We are advancing a pipeline of GalOmic RNAi medicines for a broad range of diseases with high unmet need. We are focused on faster, smarter development of RNAi medicines designed for real-world impact. Learn more at www.tangramtx.com.

Media Contact

press@tangramtx.com

Investor Relations Contact

IR@tangramtx.com